NewsMarketsBeckham-Backed Synthetic CBD Company To List On London Stock...

Beckham-Backed Synthetic CBD Company To List On London Stock Exchange On February 26


A £25m CBD company backed by footballer David Beckham’s investment firm is to list on the London Stock Exchange later this week.

Cellular Goods says it has attracted strong demand from institutional and private investors for its initial public offering to join the main market – scheduled for February 26.

The London-based company says it has raised over £13m with its IPO being 13 times oversubscribed. 

Net proceeds from the IPO will be used to fund the development of Cellular Goods’ biosynthetic cannabinoid cosmetics and sports recovery products, it says. 

‘Skin’ & ‘Movement’

Today’s announcement was accompanied by the launch of its website which shows a range of cosmetic synthetics CBD branded as ‘Skin’ products and a sports range branded under the ‘Movement’ tag

In a press release Alexis Abraham, Chief Executive Officer, said: “We are delighted with the tremendous support we have received from institutional capital and the unprecedented level of interest shown by retail investors for an IPO of this size. 

“We want to involve as many private investors as possible so that they can both be part of and benefit from our growth as we become the trusted brand in consumer cannabinoids. 

“Technology now means that ‘listening at scale’ is not just a possibility but a requirement for successful consumer brands. We firmly believe that the future of the cannabinoid industry will be driven by biosynthetic production and our significantly oversubscribed IPO is a sign of investor confidence in this future.” 

Third Cannabis LSE Listing In Weeks

Cellular has issued over 504 million shares supported by Tennyson Securities and Novum Securities as joint book-runners and brokers, with PrimaryBid acting as retail adviser. 

More than 6,000 valid applications were received under the retail offer, resulting in a significant oversubscription. Cellular says all retail investors investing up to £500 have been allocated in full.

A total of 260mln ordinary shares, representing 51.5% of the company’s issued capital on admission, will be issued at the IPO offer price of 5p a share, meaning it will have an initial market cap of £25mln.

The company’s shares are expected to commence trading under the ticker symbol CBX from 8am this Friday – February 26, subject to the approval of its application for admission to the standard listing segment of the LSE. 

Cellular Goods will be valued at a market capitalisation of £25m at launch. Its press release confirmed that David Beckham Ventures is an investor in the company with a 5% stake.

Cellular’s debut will make it the third cannabis company to launch on the LSE this month after the Financial Conduct Authority announced it was changing its listing rules last year.

The UK’s LSE debutants Kanabo Group and MGC Pharmaceuticals have both got off to strong starts – keep up with their progress by following their LSE tickers KNB and MXC.

New Leaf Opportunities was launched last year and aims to turn the UK into a world leader in medical cannabis and CBD.

It is being spearheaded by advocacy group Volteface. Its Director Paul North welcomed developments saying: “We feel that the opportunity is ripe for London to take control of the cannabis sector by making ourselves an attractive jurisdiction for regulated cannabis companies to operate in. 

“With investment comes added finance for research and development, better patient and consumer experience – and ultimately lower costs for those in need of medicine. 

“NLO partner’s Kanabo listing has been warmly received and we wish the team at Cellular Goods the best of luck with the listing.” 

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


  1. Well, now it’s time to back up natural CBD as there is so much “fuss” about novel foods and everything about it… Synthetic isn’t the way to go in my opinion, as it just gives pharmacy the chance to control everything – and studies proved that synthetic CBD is not as effective as natural and not even close when it comes to safety. I think that this investment wasn’t a good move for hemp in general, but good for profit only…
    Otherwise, as always, great article.

Comments are closed.

Latest news

European Cannabis Stocks Review: SEED Innovations Shares Spike 25%, Futura Medical Signs Commercialisation Deal, & More From Akanda

AS quarterly and full-year results continued to be published across the global cannabis industry, European stocks enjoyed a relatively...

Creso Pharma Secures Heads of Agreement With Tattoo Aftercare Company Dr Pickles

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise it has signed anon-binding,...

LYPHE Group Poised For European Expansion As It ‘Steps Into Venture Capital’ With £5m Fundraise Led By Leafy Tunnel

LYPHE Group has announced the successful closure of its latest funding round, securing £5m in capital to fund expansion...

ACMD Reveals It Hasn’t Examined Cannabis Evidence For 14 Years As Signs Of UK’s ‘Appetite For Reform’ Grows

LAST week saw the British Government reinstate its hardline position on drug policy, as Policing Minister Kit Malthouse announced...

European Cannabis Industry ‘Potentially An Even Bigger Opportunity’ Than The US, And Investors Should ‘Wake Up To The Opportunities In Their Own Backyard’

NORTH American investment in the European cannabis industry has grown at pace over the last few years, with hundreds...

Major Cannabis Supplier Faces No Prison Sentence After Direct Support From Cancard, And After Hundreds Of Cancer Patients Come Forward To Say That He...

As reported by Cancard Cancard reports that one of their card holders and well known cannabis experts, Andrew Baines, will...

Must read

You might also likeRELATED
Recommended to you